nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-B7345F82·Framework v5.10·Pipeline v0.4·Evaluated 08 Nov 2026·OECD: 3.3 Health sciences·Subfield: Endocrinology, Diabetes and Metabolism·Basis: Full text·Type: Systematic review

Iodine fortification of foods and condiments, other than salt, for preventing iodine deficiency disorders

Joseph Alvin Santos et al.Joseph Alvin Santos, Anthea Christoforou, Kathy Trieu et al.·2019·Cochrane Database of Systematic Reviews·10.1002/14651858.cd010734.pub2 ↗

Primary claim

Pooled results from RCTs showed that urinary iodine concentration significantly increased following iodine fortification (SMD 0.59, 95% CI 0.37 to 0.81; 6 RCTs, 2032 participants; moderate-quality evidence).

Supported · design-stratified trial synthesis supports the biomarker increase despite substantial heterogeneity and high-risk studies
In brief

A systematic synthesis supports increased urinary iodine from non-salt fortification, but sparse clinical evidence limits its value for implementation decisions.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Abstract

Iodine fortification of foods and condiments, other than salt, for preventing iodine deficiency

Key Claims

Primary finding · Supported

Pooled results from RCTs showed that urinary iodine concentration significantly increased following iodine fortification (SMD 0.59, 95% CI 0.37 to 0.81; 6 RCTs, 2032 participants; moderate-quality evidence).

design-stratified trial synthesis supports the biomarker increase despite substantial heterogeneity and high-risk studies

Abstract, Main results; Results, Urinary iodine concentration; Figure 6
Quote verified
Secondary · Tentative

The evidence on the effect of iodine fortification of foods, beverages, condiments, or seasonings other than salt on reducing goitre, improving physical development measures, and any adverse effects is uncertain.

clinical estimates rely principally on one small non-randomised study, with safety assessed only in a small crossover trial

Abstract, Authors' conclusions
Quote verified
Secondary · Tentative

One study reported that there were no adverse events observed during the cross-over trial (low-quality evidence).

a small, short infant nutrient-balance trial provides indirect and imprecise safety evidence

Abstract, Main results
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Broad searches support a reproducible synthesis

The search covers international and regional databases, grey literature, theses, trial registries and organisational contacts without language restrictions. Appendix 1 supplies the search strategies.

↳ Methods, Search methods; Appendix 1

#contribution

Distinct evidence map for alternative vehicles

The review synthesises non-salt iodine-fortification studies separately from established salt and supplementation evidence. It distinguishes an observed biomarker increase from unresolved clinical benefits.

↳ Background, Why it is important to do this review; Summary of findings

#positioning

Limitations shape interpretation and practice conclusions

The discussion connects absent clinical outcomes, restricted populations and unexplained heterogeneity to limits on inference. The practice conclusions explicitly request more efficacy and safety evidence before widespread implementation.

↳ Discussion, Overall completeness and applicability; Authors' conclusions, Implications for practice

Limitations

#methodological rigour

Unresolved heterogeneity complicates the certainty rating

The primary RCT urinary-iodine analysis has I² = 81%, yet its moderate-certainty rating is downgraded only for risk of bias. Post-hoc subgroup analyses do not fully explain the variability.

↳ Figure 6; Summary of findings, footnote 10; Discussion, Summary of main results

#contribution

Clinical and safety evidence remains sparse

The main positive result concerns urinary iodine rather than prevention of clinically important disorders. Goitre and growth evidence is very uncertain, and adverse-event evidence comes from one small crossover trial.

↳ Abstract, Main results; Summary of findings

#reporting

Robustness wording obscures changing effect estimates

Sensitivity analyses are described as not changing the effect, although the RCT estimate moves from SMD 0.59 to 0.73 and the non-RCT estimate from 0.25 to 0.00. The broad statistical conclusions persist, but the wording understates numerical variation.

↳ Abstract, Main results; Results, Sensitivity analysis; Analyses 3.1 and 3.2

Does this match your read? Add your assessment ↓

Nabu Commentary

The reproducible search, independent screening and extraction, and design-separated analyses support a methodologically competent synthesis. The principal result is an increase in urinary iodine, not established prevention of iodine-deficiency disorders. Substantial unexplained heterogeneity and the absence of an inconsistency downgrade temper the certainty assessment, although the lower-risk studies retain a positive biomarker effect. The discussion integrates these limits into cautious practice implications, while the sensitivity-analysis wording is less precise than the reported estimates.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
4.2±0.1

Contribution
4.0

The review supplies a distinct synthesis of non-salt iodine vehicles and separates evidence for urinary iodine from evidence for clinical benefit. Its advance remains principally a biomarker synthesis and evidence-gap map because clinically important outcomes are sparsely represented.

Background, Why it is important to do this review; Abstract; Summary of findings
Methodological Rigour
4.3

Reproducible searches, independent duplicate review processes, design-separated pooling and risk-of-bias sensitivity analysis support the score. Unexplained heterogeneity, transformed summary statistics and the absence of an inconsistency downgrade constrain the assessment below the airtight band.

Methods, Search methods and Data collection and analysis; Appendix 1; Figure 6; Summary of findings; Analysis 3.5
Reporting
4.2

The structure and certainty distinctions make the main inference followable from results to practice implications. Statements that sensitivity analyses did not change the effect and that no study assessed certain outcomes are less precise than the detailed results.

Abstract, Main results; Plain language summary; Results, Outcome measures and Sensitivity analysis; Authors' conclusions
Positioning
4.3

Prior salt and supplementation syntheses, differing goitre findings and consequential limitations are integrated into interpretation. Comparative evidence on vehicle feasibility, cost and stability is not synthesised sufficiently to guide vehicle selection.

Background, Description of the intervention; Discussion, Overall completeness and applicability and Agreements and disagreements

Lower confidence on Methodological Rigour — domain match limited.

Reliability

Caveats4 of 4 checks


Results checkNoted

One reported value does not reconcile, but the key claims do not rest on it.

Reporting and transparencyClean

A published protocol, protocol deviations, funding and competing interests are disclosed. No verified reporting or transparency finding is retained.

Conflict of interest: declared · Preregistration: declared

Reference IntegrityNoted

114 references in manuscript 82 of 87 checkable references found in an index 26 are books, websites or datasets — counted, but not index-checkable 1 could not be checked — not the same as no match found

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 08 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Metabolic and endocrine · Iodine deficiency
Type of advanceSynthesis
Route to useSuggested
AdvanceExtends
BeneficiariesSmall
CitationsFWCI 0.9
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim is supported by six independent RCTs across multiple countries showing consistent urinary iodine increases, though heterogeneity and moderate quality limit confidence.

From the paper
“would be preferred prior to any widespread implementation of this approach”

The paper identifies widespread implementation of iodine food fortification as a real-world use but does not name specific actors in its conclusions.

Pathway

National health ministries and WHO could use these findings to design food-based iodine fortification programmes in countries where salt iodisation is insufficient.

Barrier

Very low-quality evidence on clinical health outcomes and substantial heterogeneity in the biomarker data prevent confident policy implementation decisions.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Iodine concentration of organic and conventional milk: implications for iodine intake

    Bath, Button, Rayman · 2011 · Health sciences

    Primary claim

    Organic milk was 42·1 % lower in iodine content than conventional milk (median iodine concentration 144·5 v. 249·5 ng/g; P < 0·001).

    Supported
    Evidence Score
    3.8±0.1
    Reliability
    Caveats
  2. Body weight and waist circumference are differentially associated with the response to L-thyroxine treatment in primary hypothyroidism

    Funkquist, Sjöberg, Zetterberg, et al. · 2026 · Clinical medicine

    Primary claim

    The marked correlations with CSF levels of thyroxine and ORX suggest that hypothalamic mechanisms participate in the regulation of WC and weight during L-thyroxine therapy

    Tentative
    Evidence Score
    2.6±0.2
    Reliability
    Caveats
  3. Reframing menopause and menopause hormone therapy as opportunities for healthy aging

    Laura L. Gravelsins, Mateja Perović, Madeline Wood Alexander, et al. · 2026 · Clinical medicine

    Primary claim

    menopause characteristics, such as type, timing, and symptom burden, influence health outcomes and later-life disease risk

    Supported
    Evidence Score
    3.2±0.2
    Reliability
    Caveats

How the rubric works →